About Amgen
Amgen news and updates
Amgen, Inc. invested into assets : manufacturing facility in the amount of $550M in Holly Springs, North Carolina, United States on Aug 3rd 21'.
Amgen, one of the world’s leading biotechnology companies, announced plans today to invest $550 million to build a new manufacturing facility in Holly Springs, North Carolina.
Jan 1, 2021 | raleigh-wake.orgBrand Institute, Inc. partners with Amgen Foundation, Inc.
Brand Institute is proud to announce its successful partnership with AstraZeneca and Amgen in naming TEZSPIRE ™, the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of severe asthma patients.
Jan 1, 2021 | biospace.comKBC Belgium invests into Amgen Foundation, Inc.
Kbc Group Nv has invested 0.2% in Amgen Inc. (NASDAQ:AMGN).
Jan 1, 2019 | enbulletin.comArgent Financial Group invests into Amgen Foundation, Inc.
Argent Trust has invested 0.18% in Amgen Inc. (NASDAQ:AMGN).
Jan 1, 2019 | altcoinmercury.comNorthern Trust Company invests into Amgen Foundation, Inc.
Northern Trust has invested 0.45% in Amgen Inc. (NASDAQ:AMGN).
Jan 1, 2019 | enbulletin.comCarmot Therapeutics, Inc. partnered with Amgen Foundation, Inc. on Dec 6th 17'.
Carmot Therapeutics, (Berkeley, CA) announced today that it has entered into a multi-year drug discovery collaboration and licensing agreement with Amgen (Thousand Oaks, CA).
Jan 1, 2017 | carmot-therapeutics.usAmgen Foundation, Inc. partners with StoryCorps
Amgen will work with StoryCorps on the campaign.
Jan 1, 2016 | investopedia.comAmgen Foundation, Inc. invests into assets : campus in the amount of $1.5B in Rhode Island, United States
Amgen has invested more than $1.5 billion in its Rhode Island campus, adding more than 500,000 square feet of manufacturing, utility, administrative and laboratory space to the campus.
Jan 1, 2018 | amgenscience.comAmgen Foundation, Inc. partners with NHS
Amgen (NASDAQ: AMGN ) signed an agreement with U.K.'s National Health Service for its lung cancer drug Lumykras (sotorasib).
Jan 1, 2022 | seekingalpha.comAmgen Foundation, Inc. invests into assets : drug substance manufacturing facility in the amount of $550M in Holly Springs, North Carolina, United States
Amgen plans to invest $550 million into building the new drug substance manufacturing facility in Holly Springs, bringing around 355 skilled, well-paying jobs to the area, which is a preferred and fast-growing hub for the life sciences and biotech industries.
Jan 1, 2022 | marketscreener.comAmgen Foundation, Inc. invested into CancerIQ, Inc. in $14M on Mar 3rd 22'.
CancerIQ, the platform powering early cancer detection and prevention across broad patient populations, announced today it closed a $14 million Series B financing round co-led by Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures.
Jan 1, 2022 | businesswire.comAmgen Foundation, Inc. recognized as one of "America's Best Employers for Diversity" on Mar 7th 21'.
Last year, Amgen was named one of the world's best workplaces by Fortune magazine and Great Place to Work and was also named by Forbes magazine as one of "America's Best Employers for Diversity" for the fourth straight year.
Jan 1, 2022 | ncbiotech.orgAmgen Foundation, Inc. expands facilities to Durham, North Carolina, United States
Amgen announced plans to build a new $550 million biologics manufacturing center in Holly Springs in the Research Triangle Park area.
Jan 1, 2021 | biospace.comAmgen Foundation, Inc. partnered with Montreal Institute for Learning Algorithms on Mar 16th 21'.
MONTREAL — On Mar. 16, Amgen announced that it had entered into a multi-year partnership with Mila – Quebec Artificial Intelligence Institute.
Jan 1, 2021 | canadianmanufacturing.comAmgen Foundation, Inc. sells assets to Expedia Inc. in the amount of $900M
Expedia purchased the present site for $900 million from Amgen.
Jan 1, 2022 | connectcre.comAmgen Foundation, Inc. launches data based on drug Otezla
Amgen has announced new data based on its drug Otezla (apremilast), presented at the American Academy of Dermatology (AAD) congress in Boston, Massachusetts.
Jan 1, 2022 | pmlive.comAmgen Foundation, Inc. launches Aimovig Ally program and Aimovig Copay Program
While out-of-pocket costs will vary based on patient insurance status, Amgen and Novartis have launched the Aimovig Ally program and Aimovig Copay Program to help reduce costs to as low as $5 per month for commercially-insured patients and help uninsured patients identify potential access resources.
Jan 1, 2018 | neurologyadvisor.comAmgen Foundation, Inc. partners with Sanofi Genzyme
Two are already on the market, from Amgen and Regeneron, partnered with Sanofi.
Jan 1, 2022 | cnbc.comJohn Tsai will leave Amgen Foundation, Inc. on May 15th 22'.
At the moment there’s no word on job losses that may occur as a result of the reorganisation, but it has already claimed three senior executives, including chief medical officer John Tsai who is leaving the company on 15 May, four years after joining from Amgen.
Jan 1, 2022 | pharmaphorum.comAmgen Foundation, Inc. invested into assets : drug substance plant in the amount of $1B on Jan 1st 21'.
In 2021, Amgen announced plans to invest about $1 billion to build two environmentally friendly manufacturing facilities: a product assembly and packaging plant in Ohio and a drug substance plant in North Carolina.
Jan 1, 2022 | fiercepharma.comAmgen Foundation, Inc. launched Representation in Clinical Research program on Oct 1st 20'.
In October 2020, Amgen launched the Representation in Clinical Research (RISE) program to create greater equity related to clinical trial diversity.
Jan 1, 2022 | marketscreener.comAmgen Foundation, Inc. partners with Reify Health, Inc
Amgen has teamed up with cloud-based trial solutions firm Reify Health to help boost patients into its drug studies.
Jan 1, 2020 | fiercebiotech.comAmgen Foundation, Inc. is developing BGE-105 on Apr 1st 21'.
In April 2021, BioAge entered into an exclusive worldwide license agreement with Amgen, Inc. to develop and commercialize BGE-105 to ameliorate muscle aging [ link ].
Jan 1, 2022 | lifespan.ioAmgen Foundation, Inc. expands facilities to New Albany, Indiana, United States
Most notably, Intel Corp. plans to invest $20 billion in a pair of semiconductor factories about 20 miles west of Prudential's facility, while biotech giant Amgen is building a $365 million pharmaceutical plant nearby in New Albany.
Jan 1, 2022 | bizjournals.comAmgen Foundation, Inc. is developing biosimilar version of ustekinumab
Amgen is developing a biosimilar version of ustekinumab, currently named ABP 654.
Jan 1, 2022 | gabionline.netAmgen Foundation, Inc. launches Be You
AstraZeneca and Amgen have launched "Be You," their first branded DTC ad for new severe asthma med Tezspire.
Jan 1, 2022 | fiercepharma.comAmgen Foundation, Inc. has issues with violations of the securities laws
The Schall Law Firm a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amgen Inc. for violations of the securities laws.
Jan 1, 2022 | investingnews.comAmgen Foundation, Inc. has issues with securities fraud or other unlawful business practices
The investigation concerns whether Amgen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Jan 1, 2022 | prnewswire.comAmgen Foundation, Inc. is developing solid tumor treatments on Jan 1st 22'.
In January, the company teamed up with Amgen to develop solid tumor treatments.
Jan 1, 2022 | biospace.comAmgen Foundation, Inc. partners with Direct Relief International
Amgen is partnering with Direct Relief to support a pediatric cancer group with specialized packing materials and cold-chain expertise needed to bring medicines to Tanzanian children.
Jan 1, 2021 | pqmd.orgAmgen Foundation, Inc. launched data from the XGEVA on Jun 4th 17'.
Amgen on June 4 announced new data from the XGEVA (denosumab) Phase 3 ‘482 study, the largest international multiple myeloma trial ever conducted.
Jan 1, 2017 | finchannel.comAmgen Foundation, Inc. launches Avsola
In 2020, Amgen launched Avsola, a biosimilar of J&J/Merck’s blockbuster immunology medicine Remicade and in January 2021, the company launched Riabni, a biosimilar of Roche’s Rituxan.
Jan 1, 2022 | zacks.comAmgen Foundation, Inc. launched Biomarker Assist program on Apr 1st 21'.
Moreover, Amgen announced the launch of the Biomarker Assist program in April 2021 to improve access to advanced biomarker testing for non-small cell lung cancer patients.
Jan 1, 2022 | digitaljournal.comAmgen Foundation, Inc. launched two-year data from the phase I/II study of KRAS-G12C inhibitor for treating NSCLC on Apr 1st 22'.
In April, Amgen released two-year data from the phase I/II study of its KRAS-G12C inhibitor for treating NSCLC that showed a lower ORR (40.7%), a higher DCR (83.7%), a longer median DOR (12.3 months) but slightly shorter median PFS of 6.3 months.
Jan 1, 2022 | bioworld.comAmgen Foundation, Inc. received award 2022 Hope Award for Corporate Leadership on Jun 2nd 22'.
LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, today announced Amgen Inc. as the recipient of its 2022 Hope Award for Corporate Leadership.
Jan 1, 2022 | prnewswire.comJulie Lepin leaves Amgen Foundation, Inc. as Vice President, Regulatory Affairs for Oncology
Lepin joined the company from Amgen, where she was vice president, regulatory affairs for oncology.
Jan 1, 2022 | biospace.comAmgen Foundation, Inc. had issues with antitrust lawsuit on May 27th 22'.
Amgen, the maker of Neulasta, Enbrel and other pharmaceuticals, was slapped with an antitrust lawsuit Friday in Delaware District Court.
Jan 1, 2022 | law.comAmgen Foundation, Inc. partners with EUN
The Amgen Foundation, in collaboration with European Schoolnet, has launched Amgen Teach, a three-year professional development initiative, designed to further inspire and engage young people’s interest in science by strengthening the ability of secondary school teachers to use enquiry-based teaching strategies in their classrooms.
Jan 1, 2014 | amgeninspires.comAmgen Foundation, Inc. expands facilities to Holly Springs, North Carolina, United States
Amgen, a California-based biopharmaceutical company that pioneered the use of recombinant DNA technology four decades ago, is building a $550 million manufacturing plant in Holly Springs.
Jan 1, 2022 | ncbiotech.orgMakovski Silverstein left Amgen Foundation, Inc. on Dec 1st 21'.
Dr. Makovski Silverstein joins Onconova from Amgen, where she worked as Sr.
Jan 1, 2021 | yahoo.comAmgen Foundation, Inc. launches The Generative Biology Revolution
Amgen launched the first episode of its four-part podcast series called The Generative Biology Revolution.
Jan 1, 2022 | prweek.comAmgen Foundation, Inc. launched Break the Cycle’ on Jan 1st 22'.
At the beginning of 2022, AstraZeneca and Amgen launched an unbranded influencer campaign dubbed ‘Break the Cycle’ as part of their strategy for the asthma drug Tezspire.
Jan 1, 2022 | eradigm.comAmgen Foundation, Inc. acquired Merck on Jul 8th 19'.
The potential deal would cost Merck over $40 billion, the largest biopharma acquisition since Amgen purchased Allergan three years ago to the tune of $63 billion.
Jan 1, 2022 | healtheconomics.comAmgen Foundation, Inc. invested into assets : biomanufacturing facility in the amount of $365M on Jun 14th 22'.
"Amgen Inc., …a US-based global biotechnology company, recently broke ground on a $365 million biomanufacturing facility in New Albany.
Jan 1, 2022 | newarkadvocate.comPfizer, Inc. files suit against Amgen Foundation, Inc.
Pfizer is suing Amgen in Europe over a patent issue, one in which both companies have long gone back and forth.
Jan 1, 2022 | endpts.comPfizer, Inc. files suit against Amgen Foundation, Inc.
Pfizer is suing Amgen in Europe over a patent issue, one in which both companies have long gone back and forth.
Jan 1, 2022 | endpts.comAmgen Foundation, Inc. acquired Dezimapharma for $300M on Jan 1st 15'.
It was initially developed b y Dutch biotech company Dezima, which was acquired by Amgen in a $300 million deal in 2015.
Jan 1, 2020 | geekwire.comLe Goff leaves Amgen Foundation, Inc. as President
Dr. Le Goff joined Moderna from Amgen, where she served as President of the U.S. Business, driving the growth strategy with increased contributions from Repatha ® and Aimovig ®.
Jan 1, 2022 | celsion.comAmgen Foundation, Inc. acquired ChemoCentryx, Inc. for $3.7B on Jul 4th 22'.
Amgen Inc. (Nasdaq: AMGN) has agreed to pay $3.7 billion in cash — $52 a share — to acquire San Carlos-based biotech ChemoCentryx Inc. (Nasdaq: CCXI), which has a recently approved drug to treat a rare immune-system disease.
Jan 1, 2022 | bizjournals.comAmgen Foundation, Inc. launches three new data sets
Amgen (NASDAQ: AMGN) today announced three new data sets from its thoracic oncology portfolio that will be presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC) from August 6-9 in Vienna, Austria.
Jan 1, 2022 | topionetworks.comAmgen Foundation, Inc. launched data from the DeLLphi300 clinical trial on Aug 7th 22'.
Amgen (NASDAQ: AMGN) today announced new data from the DeLLphi300 clinical trial, a Phase 1 dose exploration and expansion study evaluating the safety and efficacy of investigational tarlatamab, a potential first-in-class half-life extended bispecific T-cell engager (HLE BiTE ® ) molecule targeting delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).
Jan 1, 2022 | amgen.comAmgen Foundation, Inc. launched Prolia on Jan 1st 09'.
When the biotech drugmaker Amgen launched Prolia (denosumab) in 2009, a novel monoclonal antibody biologic to be injected every six months, many hoped it would be safer.
Jan 1, 2022 | bestcaseleads.comAmgen Foundation, Inc. partnered with Lumakras on Jan 1st 21'.
In 2021, Amgen announced a clinical collaboration with Verestam Oncology to evaluate the combination of VS-6766, Verastem Oncology’s investigational dual RAF/MEK inhibitor with Lumakras in KRAS G12C-mutant non-small cell lung cancer.
May 19, 2022 | biospace.comAmgen Foundation, Inc. recognized as one of many 25 World’s Greatest Workplaces™ on Jan 1st 21'.
In 2021, Amgen was named one of many 25 World’s Greatest Workplaces™ by Fortune and Nice Place to Work™ and one of many 100 most sustainable corporations on the earth by Barron’s.
Jun 30, 2022 | newbooker.comAmgen Foundation, Inc. partnered with McKesson Corporation on Dec 1st 20'.
In December 2020, Amgen Inc. has announced a strategic partnership with McKesson.
Sep 28, 2022 | dkoding.inAmgen Foundation, Inc. launches phase 3 study of Lumakras
Gordon expects a similar uptake pattern in some European countries where biomarker testing and clinical information systems are less developed, including Spain, Italy and the U.K. Having already seen “promising early data” in the PD-L1-negative population, Amgen will launch a phase 3 study of Lumakras and chemotherapy in first-line advanced or metastatic NSCLC, he said.
Aug 5, 2022 | fiercepharma.comMirati Therapeutics, Inc. identified as competitor of Amgen Foundation, Inc.
Mirati competes with Amgen in the KRAS G12C mutant NSCLC space.
May 27, 2022 | seekingalpha.comAmgen Foundation, Inc. is developing Navtemadlin
Meanwhile, Amgen ( AMGN ), GlaxoSmithKline ( GLAXO ), Kartos Therapeutics (Private), National Cancer Institute (USA), Telios Pharmaceuticals (Private) and Vanderbilt University Medical Center collaborated to develop Navtemadlin (KRT-232), another treatment for this disease, which employs proto-oncogene protein c mdm2 inhibitors.
Nov 21, 2022 | equities.comAmgen Foundation, Inc. launches latest update to Biosimilar Trends Report
Recently, Amgen released the latest update to its Biosimilar Trends Report, detailing some of the big successes for biosimilars in the United States since their market introduction in 2015 as well as current market trends, predictions for the next phase of biosimilar competition, and advice for stakeholders going forward.
Nov 27, 2022 | centerforbiosimilars.comAmgen Foundation, Inc. launches 2021 Environmental, Social & Governance report
Amgen has released its 2021 Environmental, Social & Governance (ESG) report, providing a comprehensive overview of the many ways the Company is doing its part to build a better, healthier world.
Nov 27, 2022 | ethicalmarketingnews.comArrowhead Pharmaceuticals, Inc. sells assets to Amgen Foundation, Inc.
Pasadena-based Arrowhead Pharmaceuticals Inc. announced that New York-based life science fund Royalty Pharma has acquired a royalty interest in a drug to treat cardiovascular disease that was originally developed by Arrowhead but later sold to Thousand Oaks-based Amgen Inc.
Nov 28, 2022 | labusinessjournal.comAmgen Foundation, Inc. launched KANJINTI for the diagnosis of HER2-overexpressing adjuvant as well as metastatic breast cancer, as well as HER2-overexpressing metastatic gastric or gastro esophageal junction adenocarcinoma on Jan 1st 19'.
For example, in 2019, Allergan plc and Amgen Inc. collaborated to release KANJINTI (trastuzumab) for the diagnosis of HER2-overexpressing adjuvant as well as metastatic breast cancer, as well as HER2-overexpressing metastatic gastric or gastro esophageal junction adenocarcinoma.
Nov 24, 2022 | digitaljournal.comAmgen Foundation, Inc. acquired Horizon Therapeutics plc for $20B on Jan 1st 22'.
Amgen is in advanced talks to buy drug company Horizon Therapeutics PLC, according to people familiar with the matter, in a takeover likely to be valued at well over $20 billion and mark the largest healthcare merger of the year.
Nov 28, 2022 | yahoo.comTagari leaves Amgen Foundation, Inc. as vice president, research - therapeutic discovery
Tagari joins insitro in early 2023 from Amgen, where he has held a variety of roles since 1998, and served as vice president, research - therapeutic discovery, since 2012.
Dec 1, 2022 | businesswire.comAmgen Foundation, Inc. launched novel bispecific glucose-dependent insulinotropic polypeptide receptor antagonist and glucagon-like peptide-1 receptor agonist molecule on Dec 1st 22'.
Amgen (NASDAQ:AMGN) today announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule.
Dec 1, 2022 | yahoo.comAmgen Foundation, Inc. is developing BGE-105 for all indications on Apr 1st 21'.
In April 2021, BioAge entered into an exclusive worldwide license agreement with Amgen, Inc. to develop and commercialize BGE-105 for all indications.
Dec 5, 2022 | lifespan.ioAmgen Foundation, Inc. receives financing of $28.5B in bridge loan
Amgen Inc. secured a $28.5 billion bridge loan to fund its purchase of Horizon Therapeutics Plc, joining ranks with Broadcom Inc. and AT&T Inc. in receiving some of the biggest debt commitments for mergers and acquisitions in nearly two years.
Dec 12, 2022 | bloomberg.comAmgen Foundation, Inc. acquired Horizonph for $27.8B on Dec 1st 20'.
Horizon Pharmaceuticals Inc. is based in Chicago, Illinois and was acquired in December 2020 by Amgen for $27.8 billion.
Dec 14, 2022 | nationalinjuryadvocates.comJohnson & Johnson files suit against Amgen Foundation, Inc.
Johnson & Johnson’s Janssen unit filed a lawsuit against Amgen, claiming the latter infringed on the former’s patents when creating its ustekinumab biosimilar, and Express Scripts announced that it would add adalimumab biosimilars to formulary.
Dec 19, 2022 | centerforbiosimilars.comAmgen Foundation, Inc. is developing drugs using the platform
Amgen will have rights to develop and commercialize drugs using the platform according to the contract.
Dec 23, 2022 | koreaherald.comBank of America invests into Amgen Foundation, Inc. in $28.5B
Amgen will pay all cash for the smaller Horizon and has secured $28.5 billion in financing from Bank of America and other lenders.
Dec 28, 2022 | vcstar.comBank of America invests into Amgen Foundation, Inc. in $28.5B
Amgen will pay all cash for the smaller Horizon and has secured $28.5 billion in financing from Bank of America and other lenders.
Dec 28, 2022 | vcstar.comLegochembio partnered with Amgen Foundation, Inc. on Dec 23rd 22'.
LegoChem Biosciences, a South Korean drug company, announced on Friday that the company signed a technology transfer agreement with US multinational biopharmaceutical company Amgen to transfer antibody-drug conjugate technology.
Dec 23, 2022 | koreaherald.com